Drug Trial Radar · NCT03362697
Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women
Last checked: Nov 19, 2026Latest source record: Jun 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Dec 15, 2017
Primary completion
Dec 30, 2018
Study completion Jun 18, 2019
Sponsor
- Lead sponsor
- Innovacion y Desarrollo de Estrategias en SaludAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BioGaia AB
- First posted
- Dec 5, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prevalence of uro-genital infections during pregnancy move between 7% to 12% in developed countries, meanwhile in developing countries this figure moved between 14% and until 55%, such is the case of Mexico. Meanwhile use of antibiotics for 3 to 7 days had established as a standard of care, the use of non-antibiotic therapy, such as cranberry powder or probiotics for prevention/treatment of this conditions is scarce. Randomized controlled trial aimed to evaluate the safety and efficacy of probiotic vs. antibiotics to treat pregnant women with uncomplicated cystitis or asymptomatic bacteriuria
Conditions
- Urinary Tract Infection in Pregnancy
Interventions
ProbioticsDietary supplement
The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
AntibioticsDrug
Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical and/or Bacteriological cureTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital General Dr. Manuel Gea Gonzalez
Mexico City, Tlalpan, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.